🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

BioCardia, Inc. BCDA PHARMA

Healthcare · Biotechnology · United States
https://www.biocardia.com
Company Profile ↓
$1.11
-40.32% 1Y
Mkt Cap$16.80M
P/E-1.31
P/B6.11
52W High$2.27
52W Low$0.77
Book Value$0.18
EPS (TTM)$-0.85

Company Overview

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.

Recent Developments

  • Trailing 12 Months Year-on-year growth — revenue -100.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-
1 Year:-100.00%

Stock Price Performance

1 Year:-40.32%
6 Months:-13.28%
3 Months:+20.65%
1 Month:+13.27%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 23% of range
$0.77 $2.27
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)59.10 · Neutral
Price Performance
1M+13.27%
3M+20.65%
6M-13.28%
1Y-40.32%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Trading 51.1% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-1.31
Industry PE
24.83
Forward P/E
-1.85
PEG Ratio
-
Book Value
$0.18
Price to Book
6.11
P/S
-
EV/EBITDA
-1.36
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-100.00%
Earnings (YoY)
-

Profitability & Returns

ROCE
-
ROE
-
ROA
-
Profit Margin
0.00%
Op Margin
0.00%
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.21
EPS (TTM)
$-0.85

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
0.35
Current Ratio
0.41
Debt
$412.00K
Total Assets
$1.71M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
23.19%
Chg in Prom Hold
0.00%
FII / Inst Holding
9.50%
Chg in FII Hold
1.25%

Financial Snapshot

Enterprise Value
$16.80M
Total Revenue (TTM)
$0
EBITDA
$-7.80M
Free Cash Flow
$-4.94M
Operating Cash Flow
$-7.48M
Shares Outstanding
15.14M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 BCDA BioCardia, Inc. PHARMA 1.11 -1.31 $16.80M 0.00% - - - -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2013Jun 2013Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue ---------178.00K144.00K117.00K137.00K112.00K130.00K-------------------------
Gross Profit 38.00K69.00K--------------------------------------
Operating Income -26.00K6.00K26.00K63.00K65.00K42.00K75.00K72.00K83.00K-1.08M-1.38M-1.68M-2.88M-2.97M-3.04M-3.62M-3.25M-3.57M-3.69M-3.76M-3.23M-4.61M-3.57M-3.85M-2.97M-3.49M-2.71M-3.33M-2.50M-3.06M-3.51M-3.45M-2.60M-2.27M-1.65M-1.76M-2.73M-2.05M-1.49M-2.27M
Net Income -25.00K9.00K30.00K64.00K66.00K43.00K76.00K73.00K83.00K-1.50M-1.98M-3.25M-2.88M-2.94M-3.00M-3.58M-3.22M-3.54M-3.67M-3.75M-3.79M-4.59M-3.57M-3.85M-2.97M-3.49M-2.71M-3.33M-2.50M-3.06M-3.50M-3.42M-2.57M-2.27M-1.65M-1.74M-2.71M-2.05M-1.48M-2.26M
Diluted EPS -------------------------------------0.59---0.21
R&D Expense ---------441.00K497.00K684.00K1.03M1.29M1.70M1.96M2.03M2.26M2.17M2.22M2.01M2.79M2.22M2.47M1.84M2.36M2.24M2.19M2.30M2.14M2.38M2.31M1.87M1.24M800.00K931.00K1.53M1.37M936.00K1.24M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 012.00K---904.00K576.00K479.00K625.00K710.00K145.00K1.01M1.35M477.00K58.00K0
Gross Profit 012.00K62.00K-------------
Operating Income -583.00K-618.00K-339.00K9.00K231.00K-5.41M-7.61M-12.40M-14.10M-14.21M-15.53M-12.63M-11.90M-11.64M-8.00M-8.28M
Net Income -11.51M9.66M305.00K19.00K234.00K-6.70M-10.31M-12.31M-13.99M-14.71M-15.00M-12.62M-11.91M-11.57M-7.95M-8.23M
R&D Expense -----1.52M3.33M5.80M8.45M8.56M9.81M8.56M8.83M7.73M4.39M4.96M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Sep 2012Dec 2012Dec 2013Dec 2014Dec 2015Oct 2016Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -5.43M13.73M-13.30M13.54M13.88M4.86M-22.08M13.54M6.42M7.68M23.42M15.72M9.79M2.99M3.72M3.41M
Total Equity 14.74M3.28M12.98M-13.29M13.31M-43.12M-3.44M-20.58M11.12M3.79M2.37M19.18M10.38M4.89M-1.60M837.00K895.00K
Cash & Equivalents 4.97M127.00K12.68M12.82M13.27M13.29M3.18M3.56M24.00M21.35M12.69M5.36M5.58M21.41M12.87M7.36M1.10M2.37M2.50M
Total Liabilities -2.16M756.00K-12.00K1.00K10.00K8.30M-1.50M2.41M2.62M5.31M4.25M5.34M4.90M4.59M2.89M2.52M
Current Liabilities -------8.30M-1.44M2.33M2.55M4.00M4.25M3.71M3.58M3.61M2.32M2.43M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -4.28M-3.09M-310.00K27.00K-7.02M-5.52M-8.67M-11.07M-9.45M-12.36M-10.37M-10.56M-9.97M-7.89M-7.44M
Investing Cash Flow -1.07M16.14M900.00K0-125.00K18.92M-136.00K-66.00K-146.00K-32.00K-116.00K-70.00K-12.00K-6.00K-7.00K
Financing Cash Flow 500.00K-500.00K0-7.52M4.40M144.00K3.80M9.82M28.21M1.95M5.12M3.73M9.16M7.57M
Capital Expenditure -1.07M-137.00K-0--125.00K--136.00K-66.00K-146.00K-32.00K-116.00K-70.00K-12.00K-6.00K-7.00K
Free Cash Flow -5.35M-3.22M-310.00K--7.15M--8.81M-11.13M-9.59M-12.39M-10.48M-10.63M-9.99M-7.89M-7.44M

Ratios (Annual)

Figures in %.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -100.0%--------------
Operating Margin % --5,150.0%----598.3%-1,320.8%-2,589.8%-2,256.3%-2,001.8%-10,709.7%-1,244.3%-880.3%-2,441.1%-13,794.8%-
Net Margin % -80,516.7%----740.8%-1,789.9%-2,569.5%-2,237.9%-2,071.7%-10,347.6%-1,243.6%-880.7%-2,425.8%-13,700.0%-
ROE % -351.0%74.4%2.3%0.1%-0.5%194.6%-50.1%-110.6%-368.9%-620.6%-78.2%-121.7%-243.4%721.8%-949.3%-919.3%
ROCE % -----157.1%-36.9%-110.7%-364.5%-386.7%-81.0%-105.2%-191.7%1,875.0%-570.3%-843.8%

Shareholding Pattern

Insiders
23.19%
Institutions
9.50%
Public Float
12.37%

Top Institutional Holders

#Holder% HeldSharesValue
1 Citigroup Inc. 2.63% 397.59K $465.18K
2 CM Management, LLC 1.98% 300.00K $351.00K
3 Vanguard Capital Management LLC 0.82% 124.59K $145.77K
4 Pingora Partners LLC 0.80% 120.38K $140.85K
5 UBS Group AG 0.51% 77.62K $90.81K
6 Geode Capital Management, LLC 0.44% 66.66K $78.00K
7 Vanguard Fiduciary Trust Co 0.44% 66.27K $77.53K
8 Susquehanna International Group, LLP 0.26% 38.81K $45.41K
9 Brown Advisory Inc. 0.23% 35.54K $41.58K
10 Commonwealth Equity Services, LLC 0.15% 23.38K $27.36K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BCDA

Google News Sat, 05 Sep 2026

BioCardia (BCDA) CEO adds 800 shares in open-market buy - Stock Titan

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNbXlzMmhQM0dpOGVqOFFHYlRldjRJQU5VbnFjeHI1S2dIMWtaTW1md0dHZWR2bDFRV19NNTllOGtVNGk2RUJUai1HdEtaa25NVlhKaHdPTThuaEhIZ0pwRWFfZnFqcVhDYy1tOVdiQTZ5VVZyN1hFNFdDZHdQNG1rM191UnFwbzdaWTJtT0…

Google News Fri, 05 Jun 2026

Why Did BCDA Stock Surge More Than 50% Today? - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPeDgyS2FFenZhcWJOZ0VnbDR4ZXA2UFZwX1luaE9nR0JKYmhMY3laZVUwa3pIWlpmcHRtQnQ0VGNOa2R4Q21Ldlg2Vnlqd0hIdWVGYk5vWmdyZmdPOEJEOE5mQklvWHBBTnhnRzFsWklpVUZTd2dxZ0VoNWE3Z3NzQ3ZOY2ZUQndpd0FYeG…

Google News Fri, 05 Jun 2026

BioCardia Shares Rally After FDA Supports Regulatory Path for Heart Failure Therapy (BCDA) - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOOFZiZnVZcWFVQUE0LVYyZVJIM1ZVUkU5ZEgwdGx3QWxRQ0FmWTVOSy1LeXBUZ3NPYkgxVWk3cEJUR2dsUXpJRXFwaVM0cFV1YzRabElZVDZUZnR2M0NiRDhwTkd5bUJRWENDeC1yWXN3THZRRTBab0NyLTAxVnpzQWRLSFNab2U4YTlXSj…

Google News hu, 06 Aug 2026

Insiders In BioCardia Still Down 21% On US$1.08m Investment - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxOQjdwYm5FRU5KNmN1NkEtSVEzcl8taWZuV3Y3Sk9fYUYtN3MtM0RXSHhCNFZlZU9PbElKWU9LQ0RzQzhLZE8tQnZCbTU0alY0Ry1UX2xJelNIWVhYN2NLTml4OUNVVk40MmxneU1kQjd6aFBJcFZVSlE5U1laR011UjRNZjdYRUZMOXoyV2…

Google News Wed, 24 Jun 2026

Insider Purchase: Director at $BCDA Buys 70,200 Shares | BCDA Stock News - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQRV9xbzVmQTNHdWRUUmV3Y25kQzdMTkNaRFFNc0licnJIVVltekptSzlrT0dFZnh0TE5ndVdBRVNlYWZ0azZZMXNBdDNyel9IdDBiMkxZR1RnVHVaUHZWSDhZTzluZW5mdEdFbWlkcl9YWDAyalp5bHZaRkFJVHhkQWUyV3FRTGtGeUU5cG…

Google News ue, 26 May 2026

BCDA - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9ERTZjVk52MERYUXZEMk5zSjdGNGJ6MVR2SDc4Z3E3bHQwb05vTm5xclJYd3JtazBSY21wX2RYU3VEVVFJWmc?oc=5" target="_blank">BCDA</a>&nbsp;&nbsp;<font color="#6f6f6f">Finviz</font>…

BCDA — Frequently Asked Questions

What is the current share price of BioCardia, Inc. (BCDA)?

As of 2026-09-19 21:16 PDT, BioCardia, Inc. (BCDA) trades at $1.11 on NasdaqCM. Its 52-week range is $0.77 to $2.27.

What is the market capitalisation of BCDA?

BioCardia, Inc. (BCDA) has a market capitalisation of $16.80M on NasdaqCM.

What is the P/E ratio of BCDA?

BCDA trades at a trailing price-to-earnings (P/E) ratio of -1.31. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 6.11.

Is BCDA a good stock to buy?

This page provides a data-driven analysis of BioCardia, Inc. (BCDA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space